NCT04475601 (COVIDENZA) is a Phase 2 clinical trial of Enzalutamide Pill in COVID-19, sponsored by Andreas Josefsson.

Who is sponsoring NCT04475601?

NCT04475601 is sponsored by Andreas Josefsson.

What drugs are being tested in NCT04475601?

Interventions in NCT04475601: Enzalutamide Pill.

What condition does NCT04475601 study?

NCT04475601 studies COVID-19, Corona Virus Infection.

Is NCT04475601 still recruiting?

NCT04475601 is currently terminated. Last updated 2 June 2022.

Last reviewed 2022-06-02 · How we verify

NCT04475601: COVIDENZA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enzalutamide Treatment in COVID-19

Terminated Phase 2 Last updated 2 June 2022

What this trial tests

Phase 2 trial testing Enzalutamide Pill in COVID-19 in 42 participants. Terminated before completion.

Timeline

15 July 2020

Primary endpoint
24 March 2021

29 May 2021

Quick facts

Lead sponsor	Andreas Josefsson
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	15 July 2020
Primary completion	24 March 2021
Estimated completion	29 May 2021
Sites	6 locations across Sweden

Drugs / interventions tested

Enzalutamide Pill — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →
Corona Virus Infection — all drugs for Corona Virus Infection →

Sponsor

Andreas Josefsson — full company profile →

Who can join

50 and older, any sex, with COVID-19 or Corona Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COVID-19 is a disease with high rate of morbidity if symptomatic. There is a great need of treatments to decrease the severity. The vast majority of patients needing intensive care are men, and this may be due to the androgens, either by regulation of TMPRSS2, necessary for virus internalization, or other mechanisms. Enzalutamide is an antiandrogen inhibiting the expression of androgen regulated proteins, such as TMPRSS2. The aim of this trial is to evaluate a possible beneficial effect of short-term enzalutamide treatment of COVID-19 patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

COVID-19 and Cancer: Current Challenges and Perspectives.
Bakouny Z, Hawley JE, Choueiri TK, Peters S, et al · · 2020 · cited 201× · PMID 33049215 · DOI 10.1016/j.ccell.2020.09.018
Targeting transcriptional regulation of SARS-CoV-2 entry factors <i>ACE2</i> and <i>TMPRSS2</i>.
Qiao Y, Wang XM, Mannan R, Pitchiaya S, et al · · 2021 · cited 155× · PMID 33310900 · DOI 10.1073/pnas.2021450118
Wuhan to World: The COVID-19 Pandemic.
Kumar A, Singh R, Kaur J, Pandey S, et al · · 2021 · cited 109× · PMID 33859951 · DOI 10.3389/fcimb.2021.596201
Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19.
Deng Q, Rasool RU, Russell RM, Natesan R, et al · · 2021 · cited 82× · PMID 33681723 · DOI 10.1016/j.isci.2021.102254
Androgen regulation of pulmonary AR, TMPRSS2 and ACE2 with implications for sex-discordant COVID-19 outcomes.
Baratchian M, McManus JM, Berk MP, Nakamura F, et al · · 2021 · cited 79× · PMID 34045511 · DOI 10.1038/s41598-021-90491-1
Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide.
Li F, Han M, Dai P, Xu W, et al · · 2021 · cited 77× · PMID 33558541 · DOI 10.1038/s41467-021-21171-x
Role of miR-2392 in driving SARS-CoV-2 infection.
McDonald JT, Enguita FJ, Taylor D, Griffin RJ, et al · · 2021 · cited 75× · PMID 34624208 · DOI 10.1016/j.celrep.2021.109839
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895

Verify or expand the search:

Other trials of Enzalutamide Pill

Trials testing the same drug.

NCT05588609 — Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers · Phase 2 · terminated

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04475601 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Andreas Josefsson
Last refreshed: 2 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04475601.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing